Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IMDUR vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
~28% bound to albumin.
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
2–4 L/kg, indicating extensive tissue distribution.
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IMDUR vs ISORDIL, answered by our medical review team.
IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IMDUR and ISORDIL depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IMDUR and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.